|
1
|
Thanikachalam K and Khan G: Colorectal
cancer and nutrition. Nutrients. 11:1642019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carrato A: Adjuvant treatment of
colorectal cancer. Gastrointest Cancer Res. 2 (Suppl 4):S42–S46.
2008.PubMed/NCBI
|
|
3
|
Tauriello DV, Calon A, Lonardo E and
Batlle E: Determinants of metastatic competency in colorectal
cancer. Mol Oncol. 11:97–119. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hafizi M, Kalanaky S, Moaiery H,
Khayamzadeh M, Noorian S, Kaveh V, Gharib B, Foudazi H, Razavi M,
Jenabian A, et al: A randomized, double-blind, placebo-controlled
investigation of BCc1 nanomedicine effect on survival and quality
of life in metastatic and non-metastatic gastric cancer patients. J
Nanobiotechnology. 17:522019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang L, Li L, Yang T, Li W, Song L, Meng
X, Gu Q, Xiong C and He J: Transgelin as a potential target in the
reversibility of pulmonary arterial hypertension secondary to
congenital heart disease. J Cell Mol Med. 22:6249–6261. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun Y, Peng W, He W, Luo M, Chang G, Shen
J, Zhao X and Hu Y: Transgelin-2 is a novel target of KRAS-ERK
signaling involved in the development of pancreatic cancer. J Exp
Clin Cancer Res. 37:1662018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yin LM, Xu YD, Peng LL, Duan TT, Liu JY,
Xu Z, Wang WQ, Guan N, Han XJ, Li HY, et al: Transgelin-2 as a
therapeutic target for asthmatic pulmonary resistance. Sci Transl
Med. 10:eaam86042018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li M, Li S, Lou Z, Liao X, Zhao X, Meng Z,
Bartlam M and Rao Z: Crystal structure of human transgelin. J
Struct Biol. 162:229–236. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nohata N, Sone Y, Hanazawa T, Fuse M,
Kikkawa N, Yoshino H, Chiyomaru T, Kawakami K, Enokida H, Nakagawa
M, et al: miR-1 as a tumor suppressive microRNA targeting TAGLN2 in
head and neck squamous cell carcinoma. Oncotarget. 2:29–42. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Du YY, Zhao LM, Chen L, Sang MX, Li J, Ma
M and Liu JF: The tumor-suppressive function of miR-1 by targeting
LASP1 and TAGLN2 in esophageal squamous cell carcinoma. J
Gastroenterol Hepatol. 31:384–393. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoshino H, Chiyomaru T, Enokida H,
Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N and Nakagawa
M: The tumour-suppressive function of miR-1 and miR-133a targeting
TAGLN2 in bladder cancer. Br J Cancer. 104:808–818. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Han MZ, Xu R, Xu YY, Zhang X, Ni SL, Huang
B, Chen AJ, Wei YZ, Wang S, Li WJ, et al: TAGLN2 is a candidate
prognostic biomarker promoting tumorigenesis in human gliomas. J
Exp Clin Cancer Res. 36:1552017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mo X, Su Z, Yang B, Zeng Z, Lei S and Qiao
H: Identification of key genes involved in the development and
progression of early-onset colorectal cancer by co-expression
network analysis. Oncol Lett. 19:177–186. 2020.PubMed/NCBI
|
|
14
|
Chen WS, Leung CM, Pan HW, Hu LY, Li SC,
Ho MR and Tsai KW: Silencing of miR-1-1 and miR-133a-2 cluster
expression by DNA hypermethylation in colorectal cancer. Oncol Rep.
28:1069–1076. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dvorakova M, Nenutil R and Bouchal P:
Transgelins, cytoskeletal proteins implicated in different aspects
of cancer development. Expert Rev Proteomics. 11:149–165. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deng S, Wang J, Hou L, Li J, Chen G, Jing
B, Zhang X and Yang Z: Annexin A1, A2, A4 and A5 play important
roles in breast cancer, pancreatic cancer and laryngeal carcinoma,
alone and/or synergistically. Oncol Lett. 5:107–112. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu XH, Pan W, Kang LH, Feng H and Song YQ:
Association of annexin A2 with cancer development (review). Oncol
Rep. 33:2121–2128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang T, Peng H, Wang J, Yang J, Nice EC,
Xie K and Huang C: Prognostic and diagnostic significance of
annexin A2 in colorectal cancer. Colorectal Dis. 15:e373–e381.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He H, Xiao L, Cheng S, Yang Q, Li J, Hou
Y, Song F, Su X, Jin H, Liu Z, et al: Annexin A2 enhances the
progression of colorectal cancer and hepatocarcinoma via
cytoskeleton structural rearrangements. Microsc Microanal.
25:950–960. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu H, Kortylewski M and Pardoll D:
Crosstalk between cancer and immune cells: Role of STAT3 in the
tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chiarle R, Simmons WJ, Cai H, Dhall G,
Zamo A, Raz R, Karras JG, Levy DE and Inghirami G: Stat3 is
required for ALK-mediated lymphomagenesis and provides a possible
therapeutic target. Nat Med. 11:623–629. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kortylewski M, Kujawski M, Wang T, Wei S,
Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, et al:
Inhibiting Stat3 signaling in the hematopoietic system elicits
multicomponent antitumor immunity. Nat Med. 11:1314–1321. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chan KS, Sano S, Kiguchi K, Anders J,
Komazawa N, Takeda J and DiGiovanni J: Disruption of Stat3 reveals
a critical role in both the initiation and the promotion stages of
epithelial carcinogenesis. J Clin Invest. 114:720–728. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kusaba T, Nakayama T, Yamazumi K, Yakata
Y, Yoshizaki A, Inoue K, Nagayasu T and Sekine I: Activation of
STAT3 is a marker of poor prognosis in human colorectal cancer.
Oncol Rep. 15:1445–1451. 2006.PubMed/NCBI
|
|
25
|
Chalikonda G, Lee H, Sheik A and Huh YS:
Targeting key transcriptional factor STAT3 in colorectal cancer.
Mol Cell Biochem. Apr 18–2021.doi: 10.1007/s11010-021-04156-8.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Su X, Gao C, Feng X and Jiang M: miR-613
suppresses migration and invasion in esophageal squamous cell
carcinoma via the targeting of G6PD. Exp Ther Med. 19:3081–3089.
2020.PubMed/NCBI
|
|
28
|
Wang W, Cheng X and Zhu J: Long non-coding
RNA OTUD6B-AS1 overexpression inhibits the proliferation, invasion
and migration of colorectal cancer cells via downregulation of
microRNA-3171. Oncol Lett. 21:1932021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kaufhold S and Bonavida B: Central role of
Snail1 in the regulation of EMT and resistance in cancer: A target
for therapeutic intervention. J Exp Clin Cancer Res. 33:622014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sreekumar R, Al-Saihati H, Emaduddin M,
Moutasim K, Mellone M, Patel A, Kilic S, Cetin M, Erdemir S, Navio
MS, et al: The ZEB2-dependent EMT transcriptional programme drives
therapy resistance by activating nucleotide excision repair genes
ERCC1 and ERCC4 in colorectal cancer. Mol Oncol. 8:2065–2083. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Feng J, Cen J, Li J, Zhao R, Zhu C, Wang
Z, Xie J and Tang W: Histone deacetylase inhibitor valproic acid
(VPA) promotes the epithelial mesenchymal transition of colorectal
cancer cells via up regulation of Snail. Celll Adhes Migr.
9:495–501. 2015. View Article : Google Scholar
|
|
32
|
Zhao C, Li H, Lin HJ, Yang S, Lin J and
Liang G: Feedback activation of STAT3 as a cancer drug-resistance
mechanism. Trends Pharmacol Sci. 37:47–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shi J, Ren M, She X, Zhang Z, Zhao Y, Han
Y, Lu D and Lyu L: Transgelin-2 contributes to proliferation and
progression of hepatocellular carcinoma via regulating Annexin A2.
Biochem Biophys Res Commun. 523:632–638. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Marchler-Bauer A, Anderson JB, Derbyshire
MK, DeWeese-Scott C, Gonzales NR, Gwadz M, Hao L, He S, Hurwitz DI,
Jackson JD, et al: CDD: A conserved domain database for interactive
domain family analysis. Nucleic Acids Res. 35((Database Issue)):
D237–D240. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang Y, Ye Y, Shen D, Jiang K, Zhang H,
Sun W, Zhang J, Xu F, Cui Z and Wang S: Identification of
transgelin-2 as a biomarker of colorectal cancer by laser capture
microdissection and quantitative proteome analysis. Cancer Sci.
101:523–529. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen R, Yi EC, Donohoe S, Pan S, Eng J,
Cooke K, Crispin DA, Lane Z, Goodlett DR, Bronner MP, et al:
Pancreatic cancer proteome: The proteins that underlie invasion,
metastasis, and immunologic escape. Gastroenterology.
129:1187–1197. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang F, Van Meter TE, Buettner R, Hedvat
M, Liang W, Kowolik CM, Mepani N, Mirosevich J, Nam S, Chen MY, et
al: Sorafenib inhibits signal transducer and activator of
transcription 3 signaling associated with growth arrest and
apoptosis of medulloblastomas. Mol Cancer Ther. 7:3519–3526. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xin H, Zhang C, Herrmann A, Du Y, Figlin R
and Yu H: Sunitinib inhibition of Stat3 induces renal cell
carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
Cancer Res. 69:2506–2513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li B and Huang C: Regulation of EMT by
STAT3 in gastrointestinal cancer (review). Int J Oncol. 50:753–767.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rocha MR, Barcellos-de-Souza P,
Sousa-Squiavinato ACM, Fernandes PV, de Oliveira IM, Boroni M and
Morgado-Diaz JA: Annexin A2 overexpression associates with
colorectal cancer invasiveness and TGF-β induced epithelial
mesenchymal transition via Src/ANXA2/STAT3. Sci Rep. 8:112852018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gerke V: Annexins A2 and A8 in endothelial
cell exocytosis and the control of vascular homeostasis. Biol Chem.
397:995–1003. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Emoto K, Yamada Y, Sawada H, Fujimoto H,
Ueno M, Takayama T, Kamada K, Naito A, Hirao S and Nakajima Y:
Annexin II overexpression correlates with stromal tenascin-C
overexpression: A prognostic marker in colorectal carcinoma.
Cancer. 92:1419–1426. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sharma MR, Koltowski L, Ownbey RT,
Tuszynski GP and Sharma MC: Angiogenesis-associated protein annexin
II in breast cancer: Selective expression in invasive breast cancer
and contribution to tumor invasion and progression. Exp Mol Pathol.
81:146–156. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Emoto K, Sawada H, Yamada Y, Fujimoto H,
Takahama Y, Ueno M, Takayama T, Uchida H, Kamada K, Naito A, et al:
Annexin II overexpression is correlated with poor prognosis in
human gastric carcinoma. Anticancer Res. 21:1339–1345.
2001.PubMed/NCBI
|
|
46
|
Jia JW, Li KL, Wu JX and Guo SL: Clinical
significance of annexin II expression in human non-small cell lung
cancer. Tumour Biol. 34:1767–1771. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang CY and Lin CF: Annexin A2: Its
molecular regulation and cellular expression in cancer development.
Dis Markers. 2014:3089762014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhai H, Acharya S, Gravanis I, Mehmood S,
Seidman RJ, Shroyer KR, Hajjar KA and Tsirka SE: Annexin A2
promotes glioma cell invasion and tumor progression. J Neurosci.
31:14346–14360. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Maji S, Chaudhary P, Akopova I, Nguyen PM,
Hare RJ, Gryczynski I and Vishwanatha JK: Exosomal annexin II
promotes angiogenesis and breast cancer metastasis. Mol Cancer Res.
15:93–105. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xiu D, Liu L, Qiao F, Yang H, Cui L and
Liu G: Annexin A2 coordinates STAT3 to regulate the invasion and
migration of colorectal cancer cells in vitro. Gastroenterol Res
Pract. 2016:35214532016. View Article : Google Scholar : PubMed/NCBI
|
